New York accuses Insys of deceptively marketing opioid

[February 02, 2018] By Nate Raymond

(Reuters) - Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

New York Attorney General Eric Schneiderman alleged that the Chandler, Arizona-based drugmaker recklessly marketed its product Subsys for wider uses than the U.S. Food and Drug Administration approved and bribed doctors to prescribe it.

"At a time when the opioid epidemic was ravaging New York, Insys Therapeutics allegedly marketed a drug illegally by blatantly disregarding the grave risks of addiction and death that opioids pose," Schneiderman said in a statement.

Insys said it sought to address the challenge related to the misuse and abuse of opioids that has led to addiction and unnecessary deaths around the country.

"We intend to continue working collaboratively and constructively with all relevant authorities to resolve our outstanding governmental investigations," the company said in a statement late Thursday.

Opioids were involved in over 42,000 overdose deaths nationwide in 2016, according to the U.S. Centers for Disease Control and Prevention. President Donald Trump in October declared the problem a national public health emergency.

Insys has found itself at the center of several lawsuits and investigations focused on Subsys, an under-the-tongue spray intended for cancer patients that contains fentanyl, a synthetic opioid.

Federal prosecutors in Boston have accused seven former executives and managers at Insys including billionaire founder John Kapoor of participating in a scheme to bribe doctors to prescribe Subsys and to defraud insurers.

Prosecutors said that beginning in 2012, Kapoor, former Insys Chief Executive Michael Babich and others schemed to bribe medical practitioners by paying them to participate in sham speaker program events.

Kapoor, Babich and their co-defendants have pleaded not guilty and are scheduled to face trial in January 2019.

[© 2018 Thomson Reuters. All rights reserved.]

Copyright 2018 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.